STOCK TITAN

Oramed (NASDAQ: ORMP) COO sells 137K shares after option exercise

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Oramed Pharmaceuticals COO & CBO Joshua Hexter reported an option exercise and share sale in the company’s stock. On July 2, 2026, he exercised 50,000 stock options at $3.69 per share, receiving an equal number of common shares. On July 1, 2026, he sold 137,000 common shares at a weighted average price of $4.463 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 1,073,384 common shares and 50,000 stock options that remain outstanding.

Positive

  • None.

Negative

  • None.
Insider Hexter Joshua
Role COO & CBO
Sold 137,000 shs ($611K)
Type Security Shares Price Value
Exercise Stock option (right to buy) 50,000 $0.00 --
Exercise Common Stock 50,000 $3.69 $185K
Sale Common Stock 137,000 $4.463 $611K
Holdings After Transaction: Stock option (right to buy) — 50,000 shares (Direct, null); Common Stock — 1,073,384 shares (Direct, null)
Footnotes (1)
  1. Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.7652, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The stock options vested and became exercisable in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019.
Shares sold 137,000 shares Common Stock sale on July 1, 2026 at $4.463 average
Sale price (weighted average) $4.463 per share Open-market Common Stock sales on July 1, 2026
Options exercised 50,000 options Stock options exercised into Common Stock on July 2, 2026
Option exercise price $3.69 per share Stock option (right to buy) conversion price
Shares held after transactions 1,073,384 shares Direct Common Stock holdings following July 2, 2026
Options outstanding after exercise 50,000 options Stock option balance following July 2, 2026
Option expiration date September 12, 2029 Expiration for the reported stock option grant
Rule 10b5-1 trading plan regulatory
"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"The stock options vested and became exercisable in 16 equal installments of 6,250..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
expiration date financial
"Stock option expiration date disclosed as September 12, 2029 for the derivative security."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hexter Joshua

(Last)(First)(Middle)
1185 AVENUE OF THE AMERICAS
THIRD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
COO & CBO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026S137,000(1)D$4.463(2)1,023,384D
Common Stock07/02/2026M50,000A$3.691,073,384D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$3.6907/02/2026M50,000 (3)09/12/2029Common Stock50,000$050,000D
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.7652, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
3. The stock options vested and became exercisable in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019.
/s/ Joshua Hexter07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Oramed (ORMP) COO Joshua Hexter report?

Joshua Hexter reported exercising 50,000 stock options at $3.69 per share and selling 137,000 Oramed common shares at a weighted average price of $4.463 per share. These transactions changed his direct share and option holdings.

How many Oramed (ORMP) shares did the COO sell and at what price?

The COO sold 137,000 Oramed common shares at a weighted average price of $4.463 per share. The sale occurred through multiple transactions within a price range from $4.255 to $4.7652, as disclosed in the Form 4 footnotes.

Were Joshua Hexter’s Oramed (ORMP) share sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the 137,000 Oramed shares were sold under a Rule 10b5-1 trading plan adopted on March 30, 2026. Such plans pre-schedule trades, making the timing more routine and less discretionary.

How many Oramed (ORMP) shares does the COO hold after these transactions?

After the reported transactions, Joshua Hexter directly holds 1,073,384 Oramed common shares. The Form 4 also shows 50,000 stock options outstanding following the option exercise, providing additional potential exposure to Oramed’s equity.

What stock options did Oramed (ORMP) COO Joshua Hexter exercise?

He exercised 50,000 stock options with an exercise price of $3.69 per share, receiving 50,000 Oramed common shares. The footnotes explain these options vested in 16 equal installments of 6,250 shares starting November 1, 2019.